The voltage-gated sodium channel (SCN) gene cluster at 2q24.3 is known to be involved in a spectrum of epilepsy syndromes. Haploinsufficiency of SCN1A causes Dravet syndrome and generalised epilepsy with febrile seizures (GEFS+). Mutations in SCN2A are linked to both milder forms of epilepsy like benign familial neonatal-infantile seizures (BFNIS) and GEFS+, and to more severe forms like Dravet and Ohtahara syndromes and early onset epileptic encephalopathy (EOEE) (1) . Recently, there have been reports of gain-of-function mutations in SCN3A in association with cryptogenic partial epilepsy (2, 3) .
Duplications at 2q24.3 have been described in 10 individuals (4-11) presenting with early onset epilepsy during the first days of life. In two of these, the duplications were familial with several affected family members (4, 6) . All of the cases described in the literature except in a family described by Boutry-Kryza et al. also presented with different degrees of intellectual disability (ID), and all also involved neighbouring genes apart from the sodium channel gene cluster.
Here, we report eight new cases of 2q24.3 duplication from four different families. The data presented indicate that whole gene duplication of SCN2A causes early onset epilepsy, but does not cause the ID reported in previously studied patients with 2q24.3 duplications.
Methods

Microarray analysis
Chromosomal microarray analyses (CMA) were performed using Affymetrix CytoScan HD (Affymetrix Inc, Santa Clara, CA) for case 1 (family 1), 1 Mb BAC-PAC microarray (Leuven design) for case 2 (family 2) (12), SurePrint G3 Human CGH microarray 60 K (Agilent, Santa Clara, CA) for case 3 and Agilent custom array with 5 probes per exon as part of the UK DDD study for case 4. Analyses procedures were carried out in accordance with the respective manufacturer's instructions. Parental consent was obtained. Patients data have been submitted to DECIPHER (https://decipher.sanger.ac .uk/).
Follow-up assays
In family 1 and 2, Fluorescence in situ hybridization (FISH)-analysis was performed on metaphase spreads using BAC probes within each respective deleted region and standard techniques [Family 1: RP11-343P23, RP11-801I18, RP1-23D17 (BlueGnome, Illumina, San Diego, CA); Family 2: RP11-272E3, RP11-576I16, RP11-2I8 (Wellcome Trust Sanger Institute, Cambridge, UK)].
Quantitative polymerase chain reaction (qPCR) was carried out in case 3 for parental analysis. In case 4, a dosage assay was performed comparing amplicons of SCN2A exons 2-14 with exons 1 and 15 and three control amplicons from other regions of the genome.
Results
Clinical features of patients are summarised in Table 1 .
Case 1 (family 1)
Three days after birth, this female had her first seizure. Her older sister and mother had presented in the same manner with neonatal onset of seizures during their first days of life. The seizures were successfully treated initially with phenobarbital and thereafter topiramate.
At the age of 1 year, the medication was discontinued in both sisters who remained seizure free. Both sisters reached the milestones within normal time range. The older sister started talking at 2 years of age and walked at the age of 14 months. None of the sisters, nor the mother, shows any dysmorphic features or presented any signs of a developmental delay (DD).
CMA revealed a 507 kb interstitial duplications at 2q24.3 (arr[hg19] 2q24.3(165.798,270-166.304,847)x3) ( Fig. 1 ) in both sisters and their mother, only involving SCN2, SCN3 and the 5 ′ part of SLC38A11. Analysis of the grandmother could not reveal any pathogenic copy number variations (CNV). The grandfather was not available for analysis. FISH-analysis of the mother showed that the duplication was in tandem. FISH-analysis of the grandmother did not reveal any translocation event or inversion of chromosome 2.
Case 2 (family 2)
In this family, two brothers and their father all presented with neonatal seizures. Both boys had generalised tonic-clonic seizures from their third day of life, which was successfully treated first by phenobarbital and phenytoin sodium and later by valproate sodium. Seizures ceased at 2 years of age. They are both severely intellectually disabled, autistic and had a severely delayed speech and language development where communication is still poor. Furthermore, hyperactivity and anxiety have also been noticed. Both boys also have a wide mouth with a thick upper lip and everted lower lip vermillion. At the age of 18 years, the tonic-clonic seizures reappeared in the older brother after being free of any seizures for 12 years. He is presently treated with Depakine.
CMA detected a 4. (Fig. 1 ) in the two affected bothers and their father. Because their father, who has a normal development, is also carrier of this microduplication, it is not considered as the etiologic cause of his sons' DD. The duplication could not be detected in the paternal grandparents.
Case 3
This 6 years old female, born to non-consanguineous parents, had seizures on her second day of life. She was treated with antiepileptic drugs, i.e. phenobarbital, and was seizure free for a year and thereafter. She had a generalised DD, microcephaly (head circumference (Fig. 1) . The duplication could not be detected in the parents by qPCR.
Case 4
In this 14 year old boy, there was mild delay in motor milestones; he walked at the age of 23 months. Tonic-clonic seizures appeared at the age of 5 years and lasted until the age of 11. Seizures tended to be nocturnal and were successfully treated with Valproate. On starting school, he was noted to be clumsy and to have speech delay. He has gone on to have moderate ID, and attention deficit hyperactivity disorder (ADHD) which is treated with methylphenidate. He has relatively long fingers and flat feet, and does not show any facial dysmorphic features. Brain magnetic resonance imaging (MRI) shows a persistent cavum septum pellucidum, some small areas of high signal intensity in the peri-ventricular region and a mild atrophy. CMA detected a de novo 26 kb duplication at 2q24.3 with both breakpoints located within the SCN2A gene [arr[hg19] 2q24.3 (166152059-166198692)x3] (Fig. 1) , deleting exon 2-14. Dosage analysis confirmed the duplication in the patient and its absence in his parents.
Discussion
Here, we report on eight further individuals with duplications at 2q24.3 out of which six individuals belong to two different families. In all but one case, epileptiform activity started during the first days of life and ceased after 1-2 years. However, in one case, seizures reappeared after 12 years. All cases presented with tonic-clonic seizures. Patient 4 presents with the smallest duplication detected so far in the region, only involving part of SCN2A. Both breakpoints are situated within the actual gene. In all the other cases, including previously published cases, breakpoints are located outside of SCN2A. Moreover, case 4 is atypical in that he presents with a moderate ID and a later onset of seizures at 5 years of age. No other investigations have so far identified an alternative cause for his symptoms, including whole-exome sequencing. Hypothetically, the intragenic duplication in patient 4 might cause its effect through an alternative genetic mechanism, affecting the function of the protein in a different way. However, no functional work to prove this has been undertaken.
In family 1, two sisters and a mother are all carriers of an identical duplication just involving SCN2A, SCN3A and SLC38A11. None of them presented any signs of DD or cognitive impairment.
In family 2, two brothers are presenting with a severe ID and neonatal onset generalised tonic-clonic seizures. Their father is a carrier of an identical duplication. Like his sons, he had benign neonatal seizures, but does not show any signs of ID. In this family, the duplication is larger in size and apart from the genes in family 1 it also encompasses 23 additional genes.
The de novo duplication detected in case 3 is considerably larger in size than in the two familial cases, thus also involving more genes that might influence development. This girl has neonatal seizures as well as a moderate ID.
A majority of the truncating and de novo missense SCN2A mutation associates with a more severe phenotype, like EOEE, Dravet and Ohtahara syndrome, while BFNIS and GEFS+ seem to correlate with inherited missense mutations (1) . By reviewing and calculating the physico-chemical difference in 1300 SCN mutations, of which 29 were located in SCN2A, Brunklaus et al. showed that higher Grantham scores were seen in missense mutations for the more severe phenotypes compared to the missense mutations in BFNIS (14) . A duplication, if not disrupting the reading frame of a protein, would have a minor effect on the Grantham score, which would explain the less severe form of epilepsy seen in the whole gene duplication of SCN2A. Overall, duplications have shown to be associated with less severe phenotypes, like what is seen in the reciprocal deletion/duplication of 22q11.2.
Including the cases presented here, there are now all together five cases that do not include SCN1A (Fig. 1b) . It has been proposed that duplication of SCN1A might modify the onset of seizures to be delayed. Comparing the known 14 2q24-duplication cases, inclusion of SCN1A or not do not seem to influence the onset of epilepsy. Mutations in SCN2A are generally associated with BFNIS with an onset around 3 months. Benign familial neonatal seizures (BFNS) present before the fifth day of life and are normally associated with mutations in KCNQ2 and KCNQ3. In SCN1A-related seizure disorders onset is usually at 6 months. Interestingly, in all present and the previously reported cases with SCN2A whole gene duplication, seizures appear at the second to third day of life, more resembling what has been described for BFNS. SCN1A is expressed in the γ-aminobutyric acid (GABA)ergic neurons, whereas SCN2A is expressed at the axon initial segments (AIS) in excitatory neurons, where the different isoforms are known to be temporally expressed. A high expression induced by the duplication during a neonatal vulnerable window might here explain the early onset. The complete remission could be explained by reorganisation of the AIS during development where SCN8A is presumed to replace SCN2A in the distal AIS (13) . However, further studies are warranted to further elucidate the underlying mechanisms.
In most previously published cases, patients showed different degrees of DD and in a majority also ID (4, 5, (7) (8) (9) (10) (11) . However, in the maternally inherited duplication reported by Boutry-Kryza et al., there was a family history of neonatal epilepsy affecting 10 family members (4) . In all of these individuals, cognitive development was reported to be normal. The duplication neither involved SCN3A nor SCN1A. In the family reported by Heron et al., three siblings presented with neonatal seizures together with ID (6) . One brother presented only with ID and no signs of neonatal epilepsy. The mother had a history of neonatal seizures but no ID. This data together with the data presented in this study further prove that whole gene duplication of SCN2A can be linked to early onset epilepsy or more specifically BFNS. However, whole gene duplication of SCN2A does not cause ID.
